From research to care: Teoresi Group joins PROGRESS BNCT@CNAO to advance innovation in cancer therapies
CorporateTeoresi Group (formerly HiFuture S.r.l.) is participating in PROGRESS BNCT@CNAO (ID 6170035),a research project dedicated to developing the new BNCT centre at the National Centre for Oncological Hadrontherapy. The initiative receives financial support from the European Union, the Italian Republic and Regione Lombardia, under Regione Lombardia’s 2021–2027 ERDF Regional Programme, through the Collabora & Innova call.
The project brings together expertise from research, clinical institutions and industry to promote innovation in advanced cancer therapies in Lombardy.
Towards new treatment options
PROGRESS BNCT@CNAO aims to create an integrated preclinical ecosystem dedicated to BNCT, or boron neutron capture therapy, and to support the development of technologically advanced treatment options for patients with hard-to-treat cancers, such as recurrent head and neck tumours.
Over the 27-month project, the partners will work on preparing the Investigator’s Brochure, the expected outcome upon completion of the activities. This document is an essential prerequisite for initiating the clinical investigation, which will be subject to review by the relevant authorities.
Teoresi Group’s contribution
Teoresi contributes to the project through its expertise in artificial intelligence, risk analysis and software integration, focusing on three areas of activity.
The first involves automating organ segmentation using artificial intelligence to identify and delineate human organs in medical images for BNCT treatment.
The second involves supporting the application of FMEA methodology to the entire therapy delivery process, jointly with CNAO and in accordance with ISO 14971 and ISO 14155. This methodology helps analyse potential failure modes and their effects, contributing to the management of treatment-related risks.
The third concerns the software integration of BNCT into CNAO’s clinical and management systems, supporting the incorporation of the therapy into the centre’s operational workflows.
A collaboration between research, clinical practice and industry
The project is led byFondazione CNAO – National Centre for Oncological Hadrontherapy, alongside Teoresi Group, Fondazione IRCCS Policlinico San Matteo, Raylab S.r.l., Visiorobotics S.r.l. and ELSE Solutions S.r.l.
The partnership combines complementary expertise to support the development of the new BNCT facility and prepare the groundwork for clinical investigation.
For more information about the 2021–2027 ERDF Regional Programme and the Collabora & Innova call, visit the Regione Lombardia website.
